No reason to assume they failed. Similar to how they didn’t PR the insufflation results, they may be holding the cards on this close to the chest while they prepare the filing. Nasrat did mention on the last call - “we’ll announce filings and approvals.” Something like that.
I hoped they would release the results but if these CNS ANDAs are what we think they are, that means these are billion or multi-billion dollar drug markets. If them keeping a low profile is to establish a better market position at and after launch, I’m fine with that. More revenues should drive the price higher down the road than announcing trial results now, honestly.
News 
Market Data 
Discover 
